Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity

循环骨髓细胞簇对抗肿瘤免疫的影响

基本信息

  • 批准号:
    10322156
  • 负责人:
  • 金额:
    $ 69.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-01-01 至 2025-12-31
  • 项目状态:
    未结题

项目摘要

Durable outcomes in subsets of solid cancer patients treated with immune checkpoint inhibitors (ICI) or adoptive cell transfer (ACT) immunotherapy has driven interest in gaining a better understanding of resistance mechanisms that could identify novel druggable targets. Myeloid-derived suppressor cells (MDSC) have emerged as one such barrier based on their ability to inhibit innate and adaptive immunity. While elevated blood MDSC are recognized as a poor prognostic indicator in cancer patients, it is widely thought that the main effector site for MDSC is within the tumor microenvironment (TME). This is in line with the well-documented contact- dependent mechanisms involving short-lived intermediates that underlie known mechanisms of T cell suppression by MDSC. Our published and preliminary studies enlarge on this view, showing that MDSC also function outside the TME through an unprecedented mechanism of intravascular immune suppression. The proposed study builds on our discovery that circulating MDSC initiate contact-dependent cleavage of the L- selectin homing receptor on target T cells that substantially reduces antigen-driven expansion of cytotoxic T cells in lymph nodes. We further found that L-selectin loss coincides with the formation of stable MDSC clusters in the blood of murine tumor models and advanced cancer patients. We term these new structures circulating myeloid cell (CMC) clusters. These observations led us to hypothesize that CMC clusters are an unrecognized functional niche for systemic immune suppression in cancer. To test this hypothesis, we will first determine if blood-borne MDSC target not only naïve T cells, but more broadly attack stem cell memory and central memory T cells and natural killer cells that each require L-selectin for their antitumor activity. Secondly, we will determine if CMC clusters are the active site of L-selectin cleavage by using a multipronged genetic approach to examine L-selectin fate following disruption of MDSC-T cell conjugate formation in vivo. These mechanistic studies center on β2 integrins that are highly expressed by MDSC but are normally inactive on leukocytes in fast-flowing blood under non-pathological conditions. Thirdly, we will examine the translational relevance of CMC clusters during ICI or ACT therapy in a preclinical model in which blood is the primary effector site for MDSC due to their exclusion from the TME (by blocking chemokine-directed trafficking) and spleen (by splenectomy). We will deplete circulating MDSC in this model using antibodies or a clinically relevant liver-X-receptor agonist that induces MDSC-intrinsic apoptosis to establish if blood-borne MDSC contribute to therapeutic resistance. Complementary studies will test the hypothesis that combining the analysis of circulating MDSC with CMC clusters and/or T cell L-selectin will formulate an immunosuppressive signature that predicts response to first-line therapy in metastatic cancer patients. The proposed studies will provide new insights into an unprecedented function of circulating myeloid cells and could lead to the consideration of CMC clusters as a functional biomarker for prognostication or preselection of patients that would benefit from MDSC-depleting regimens during cancer immunotherapy.
接受免疫检查点抑制剂(ICI)或过继治疗的实体癌症患者亚群的持久结果 细胞转移(ACT)免疫疗法引起了人们对更好地了解耐药性的兴趣 可以识别新的可用药靶点的机制。髓系来源的抑制细胞(MDSC)有 根据它们抑制先天免疫和获得性免疫的能力,出现了这样的障碍。当血液升高时 MDSC被认为是癌症患者预后不良的指标,被广泛认为是主要的影响因素 MDSC的部位在肿瘤微环境(TME)内。这与有充分记录的联系方式一致- 涉及短寿命中间体的依赖机制是T细胞已知机制的基础 由MDSC进行抑制。我们已发表的和初步的研究扩大了这一观点,表明MDSC也 通过一种前所未有的血管内免疫抑制机制在TME之外发挥作用。这个 拟议的研究建立在我们的发现基础上,循环中的MDSC启动了L的接触依赖性切割- 靶T细胞上的选择素归巢受体可显著减少抗原驱动的细胞毒性T细胞的增殖 在淋巴结里。我们进一步发现,L-选择素的丢失与稳定的MDSC团簇的形成是一致的。 小鼠肿瘤模型和晚期癌症患者的血液。我们称这些新结构为循环髓系 细胞(CMC)簇。这些观察结果使我们假设CMC星团是一种无法识别的功能 癌症全身性免疫抑制的利基。为了验证这一假设,我们将首先确定血液传播 MDSC不仅针对幼稚的T细胞,而且更广泛地攻击干细胞记忆和中央记忆T细胞 自然杀伤细胞,每个细胞都需要L-选择素来发挥抗肿瘤活性。其次,我们将确定CMC是否 用多管齐下的遗传学方法检测L-选择素的活性部位 体内MDSC-T细胞结合物形成中断后的命运。这些机理研究以β2为中心 在快速流动的血液中,MDSC高表达但通常在白细胞上不活跃的整合素 非病理状态。第三,我们将在ICI期间检查CMC集群的翻译相关性 临床前模型中的ACT治疗,在该模型中,由于MDSC的排斥,血液是MDSC的主要效应部位 来自TME(通过阻断趋化因子导向的运输)和脾(通过脾切除)。我们将耗尽 在这个模型中使用抗体或临床相关的肝X受体激动剂诱导循环MDSC MDSC的内源性凋亡以确定血源性MDSC是否与治疗耐药有关。互补性 研究将检验这样一种假设,即结合循环MDSC与CMC簇和/或T细胞的分析 L-选择素将制定一种免疫抑制签名,预测转移性肿瘤一线治疗的反应 癌症患者。拟议的研究将为了解循环这一前所未有的功能提供新的见解 并可能导致考虑将CMC簇作为预测的功能生物标记物 或预先选择在癌症免疫治疗期间将受益于MDSC耗尽方案的患者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Scott I. Abrams其他文献

Differences in Immune Cell Populations between Individuals with or without MGUS
  • DOI:
    10.1182/blood-2024-206171
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Sawyer Bawek;Janine M. Joseph;Alan Hutson;Sarah Parker;Joseph D. Tario Jr;Hamza Hassan;Scott I. Abrams;Jens Hillengass
  • 通讯作者:
    Jens Hillengass
Influence of interferon γ on modulation of Fas expression by human colon carcinoma cells and their subsequent sensitivity to antigen-specific CD8+ cytotoxic T lymphocyte attack
  • DOI:
    10.1007/s002620000105
  • 发表时间:
    2000-06-01
  • 期刊:
  • 影响因子:
    5.100
  • 作者:
    Elke S. Bergmann-Leitner;Scott I. Abrams
  • 通讯作者:
    Scott I. Abrams
Immune response to a carcinoembryonic antigen polynucleotide vaccine.
对癌胚抗原多核苷酸疫苗的免疫反应。
  • DOI:
  • 发表时间:
    1994
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    R. Conry;A. Lobuglio;Judy Kantor;Jeffrey Schlom;F. Loechel;S. Moore;L. Sumerel;D. L. Barlow;Scott I. Abrams;David T. Curici
  • 通讯作者:
    David T. Curici
Immune Markers of Multiple Myeloma Patients Demonstrate Significant Change after Participation in Six-Month Physical Activity Intervention
  • DOI:
    10.1182/blood-2022-167655
  • 发表时间:
    2022-11-15
  • 期刊:
  • 影响因子:
  • 作者:
    Janine M. Joseph;Michaela Hillengass;Hillary Jacobson;Joseph D. Tario;Kristopher Attwood;Adrienne Groman;Rikki Cannioto;Bryan Wittmeyer;Kirsten Moysich;Scott I. Abrams;Jens Hillengass
  • 通讯作者:
    Jens Hillengass
Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules.
通过表达 B7-1 或 B7-2 共刺激分子的重组痘苗病毒诱导抗肿瘤免疫。
  • DOI:
  • 发表时间:
    1994
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    J. Hodge;Scott I. Abrams;J. Schlom;Judy Kantor
  • 通讯作者:
    Judy Kantor

Scott I. Abrams的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Scott I. Abrams', 18)}}的其他基金

Development of a Novel Immunotherapy Platform for Triple-Negative Breast Cancer
开发针对三阴性乳腺癌的新型免疫治疗平台
  • 批准号:
    10463811
  • 财政年份:
    2021
  • 资助金额:
    $ 69.42万
  • 项目类别:
Development of a Novel Immunotherapy Platform for Triple-Negative Breast Cancer
开发针对三阴性乳腺癌的新型免疫治疗平台
  • 批准号:
    10287834
  • 财政年份:
    2021
  • 资助金额:
    $ 69.42万
  • 项目类别:
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity
循环骨髓细胞簇对抗肿瘤免疫的影响
  • 批准号:
    10543820
  • 财政年份:
    2021
  • 资助金额:
    $ 69.42万
  • 项目类别:
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry
肿瘤免疫环境和乳腺癌差异:针对非洲和欧洲血统女性的多学科研究
  • 批准号:
    10653186
  • 财政年份:
    2020
  • 资助金额:
    $ 69.42万
  • 项目类别:
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry
肿瘤免疫环境和乳腺癌差异:针对非洲和欧洲血统女性的多学科研究
  • 批准号:
    10171569
  • 财政年份:
    2020
  • 资助金额:
    $ 69.42万
  • 项目类别:
Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry
肿瘤免疫环境和乳腺癌差异:针对非洲和欧洲血统女性的多学科研究
  • 批准号:
    10404988
  • 财政年份:
    2020
  • 资助金额:
    $ 69.42万
  • 项目类别:
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines
用于 MHC-I 限制性癌症肽疫苗的钴卟啉纳米脂质体佐剂
  • 批准号:
    10320831
  • 财政年份:
    2020
  • 资助金额:
    $ 69.42万
  • 项目类别:
A Cobalt Porphyrin Nanoliposome Adjuvant for MHC-I-Restricted Cancer Peptide Vaccines
用于 MHC-I 限制性癌症肽疫苗的钴卟啉纳米脂质体佐剂
  • 批准号:
    10557071
  • 财政年份:
    2020
  • 资助金额:
    $ 69.42万
  • 项目类别:
Multidisciplinary Approaches to Tumor Immunology
肿瘤免疫学的多学科方法
  • 批准号:
    10248383
  • 财政年份:
    2019
  • 资助金额:
    $ 69.42万
  • 项目类别:
Multidisciplinary Approaches to Tumor Immunology
肿瘤免疫学的多学科方法
  • 批准号:
    10472619
  • 财政年份:
    2019
  • 资助金额:
    $ 69.42万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 69.42万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 69.42万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 69.42万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 69.42万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 69.42万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 69.42万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 69.42万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 69.42万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 69.42万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 69.42万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了